Thursday, January 19, 2023 9:49:53 AM
Bid x Size
$271.06 x 1 Ask x Size $272.91 x 3
Volume 48,899
https://stockcharts.com/h-sc/ui?s=BGNE
BeiGene Says Brukinsa Gets UK Marketing Authorization for Chronic Lymphocytic Leukemia, Marginal Zone Lymphoma
MT NEWSWIRES
08:38 AM EST, 01/19/2023 (MT Newswires) -- BeiGene (BGNE) said Thursday that the UK Medicines and Healthcare products Regulatory Agency has granted marketing authorizations for Brukinsa for the treatment of both chronic lymphocytic leukemia and marginal zone lymphoma.
(con't)
Recent BGNE News
- BeiGene Demonstrates Global Progress in 2023 Responsible Business & Sustainability Report • Business Wire • 04/26/2024 02:34:00 PM
- Globaler Onkologie-Innovator BeiGene präsentiert auf der ASCO-Jahrestagung 2024 neue Daten aus dem gesamten Portfolio für Hämatologie und solide Tumore • Business Wire • 04/25/2024 11:11:00 AM
- BeiGene, innovateur mondial en oncologie, présente de nouvelles données sur l’ensemble de son portefeuille en hématologie et en tumeurs solides lors de la réunion annuelle de l’ASCO 2024 • Business Wire • 04/25/2024 11:10:00 AM
- Global Oncology Innovator BeiGene Highlights New Data across Hematology and Solid Tumor Portfolio at 2024 ASCO Annual Meeting • Business Wire • 04/24/2024 08:01:00 PM
- BeiGene erhält von der EU-Kommission die Zulassung für Tislelizumab zur Behandlung von nicht kleinzelligem Lungenkrebs • Business Wire • 04/23/2024 11:31:00 PM
- BeiGene reçoit l’approbation de la Commission européenne pour le tislelizumab dans le traitement du cancer du poumon non à petites cellules • Business Wire • 04/23/2024 11:31:00 PM
- BeiGene Receives European Commission Approval for Tislelizumab as Treatment for Non-Small Cell Lung Cancer • Business Wire • 04/23/2024 10:00:00 AM
- BeiGene、化学療法後の進行性または転移性食道扁平上皮癌の治療のためのTEVIMBRA®のFDA承認取得 • Business Wire • 03/16/2024 03:18:00 PM
- 百濟神州喜獲FDA批准,TEVIMBRA®將用於晚期或轉移性食管鱗狀細胞癌在化療後的治療 • Business Wire • 03/15/2024 09:13:00 PM
- BeiGene reçoit l'approbation de la FDA pour TEVIMBRA® dans le traitement du carcinome épidermoïde de l’œsophage avancé ou métastatique après une chimiothérapie • Business Wire • 03/15/2024 08:02:00 PM
- BeiGene erhält FDA-Zulassung für TEVIMBRA ® zur Behandlung des fortgeschrittenen oder metastasierten Plattenepithelkarzinoms der Speiseröhre nach vorheriger Chemotherapie • Business Wire • 03/15/2024 06:06:00 AM
- BeiGene Receives FDA Approval for TEVIMBRA® for the Treatment of Advanced or Metastatic Esophageal Squamous Cell Carcinoma After Prior Chemotherapy • Business Wire • 03/14/2024 08:28:00 PM
- マックス財団、ベイジーン、ベイジーン財団の協力により、低・中所得国の慢性リンパ性白血病患者にBRUKINSA®を初回投与 • Business Wire • 03/14/2024 02:23:00 PM
- The Max Foundation、BeiGene和BeiGene Foundation共同向中低收入國家的慢性淋巴性白血病病患提供首批BRUKINSA®藥物 • Business Wire • 03/14/2024 09:31:00 AM
- Erste Dosen von BRUKINSA ® für Patienten mit chronischer lymphatischer Leukämie in Ländern mit niedrigem und mittlerem Einkommen im Rahmen der Zusammenarbeit von The Max Foundation, BeiGene und der BeiGene Foundation • Business Wire • 03/13/2024 07:01:00 PM
- Les premières doses de BRUKINSA® sont administrées à des patients atteints de leucémie lymphoïde chronique dans des pays à revenus faibles et moyens, grâce à la collaboration de la Max Foundation, de BeiGene et de la BeiGene Foundation • Business Wire • 03/13/2024 07:01:00 PM
- First Doses of BRUKINSA® provided to Patients with Chronic Lymphocytic Leukemia in Low- and Middle-Income Countries Under Collaboration of The Max Foundation, BeiGene, and the BeiGene Foundation • Business Wire • 03/13/2024 12:00:00 PM
- BeiGene Announces FDA Accelerated Approval of BRUKINSA for the Treatment of Relapsed or Refractory Follicular Lymphoma • Business Wire • 03/07/2024 10:19:00 PM
- BeiGene to Present Clinical and Preclinical Data from Broad Portfolio and Pipeline at AACR Annual Meeting 2024 • Business Wire • 03/06/2024 11:00:00 AM
- ベイジーン、2023年第4・四半期および通期決算と事業に関する最新情報を発表 • Business Wire • 02/29/2024 04:17:00 PM
- BeiGene Announces New Efficacy Analysis Comparing BRUKINSA® vs Acalabrutinib in Relapsed or Refractory Chronic Lymphocytic Leukemia • Business Wire • 02/29/2024 03:00:00 PM
- BeiGene publie ses résultats financiers du quatrième trimestre et de l’exercice 2023 et ses mises à jour commerciales • Business Wire • 02/29/2024 12:56:00 AM
- BeiGene meldet Finanzergebnisse für das vierte Quartal und das Gesamtjahr 2023 sowie aktuelle Geschäftsinformationen • Business Wire • 02/28/2024 06:13:00 PM
- BeiGene to Present at Upcoming Investor Conferences • Business Wire • 02/28/2024 01:05:00 PM
- ベイジーン、非小細胞肺がん治療薬チスレリズマブに対してCHMPから肯定的意見を受領 • Business Wire • 02/28/2024 12:43:00 PM
FEATURED Cannabix Technologies Launches New Compact Breath Logix Workplace Series and Prepares for Delivery to South Africa • May 7, 2024 8:51 AM
Moon Equity Holdings, Corp. Announces Acquisition of Wikolo, Inc. • MONI • May 7, 2024 9:48 AM
NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • NNVC • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM